Geron (NASDAQ:GERN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Geron (NASDAQ:GERN) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.03) by $0.02, Zacks reports. Geron had a negative return on equity of 28.86% and a negative net margin of 46.65%.

Here are the key takeaways from Geron’s conference call:

• Rytelo Q1 net revenue was $61.8M (up 31% YoY, 8% QoQ), demand grew ~6% QoQ, footprint expanded to ~1,450 prescribing accounts, and management says it is on track for 2026 revenue guidance of $220–$240M.
• The phase III IMpactMF trial is fully enrolled with an interim overall?survival event trigger expected in H2 2026, and management says a positive interim could materially strengthen imetelstat’s disease?modifying profile and support broader MDS uptake.
• Geron is evaluating multiple go?to?market models for Europe (not pursuing a large internal build?out), is conducting HTA/pricing work, and expects to announce its European commercial plan by year?end.
• Gross?to?net deductions rose to 21% (from 13% a year ago) due to increased 340B utilization and GPO contracting and are expected to remain in the low?to?mid 20s for 2026, which pressures realized net revenue.
• Total operating expenses declined ~9% YoY to $50.4M in Q1 and management reiterated Opex guidance of $230–$240M; cash was ~$341M at quarter end after planned bonus, severance and CMC investments.

Geron Stock Down 4.2%

GERN stock traded down $0.07 during midday trading on Wednesday, hitting $1.58. 21,455,098 shares of the company’s stock were exchanged, compared to its average volume of 15,212,574. The company has a current ratio of 4.66, a quick ratio of 3.62 and a debt-to-equity ratio of 0.53. Geron has a 12-month low of $1.04 and a 12-month high of $2.01. The firm has a 50 day moving average price of $1.60 and a 200-day moving average price of $1.43. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -12.15 and a beta of 0.68.

Institutional Investors Weigh In On Geron

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Virtu Financial LLC purchased a new stake in Geron during the 4th quarter worth approximately $171,000. Invesco Ltd. increased its holdings in Geron by 27.6% during the 4th quarter. Invesco Ltd. now owns 1,225,658 shares of the biopharmaceutical company’s stock worth $1,618,000 after purchasing an additional 265,197 shares during the last quarter. Mercer Global Advisors Inc. ADV increased its holdings in Geron by 104.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 91,619 shares of the biopharmaceutical company’s stock worth $121,000 after purchasing an additional 46,801 shares during the last quarter. XTX Topco Ltd increased its holdings in Geron by 56.1% during the 4th quarter. XTX Topco Ltd now owns 258,397 shares of the biopharmaceutical company’s stock worth $341,000 after purchasing an additional 92,881 shares during the last quarter. Finally, Virtus Investment Advisers LLC increased its holdings in Geron by 76.4% during the 4th quarter. Virtus Investment Advisers LLC now owns 502,509 shares of the biopharmaceutical company’s stock worth $663,000 after purchasing an additional 217,641 shares during the last quarter. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently commented on GERN. Weiss Ratings reissued a “sell (e+)” rating on shares of Geron in a research report on Monday, April 27th. TD Cowen reissued a “buy” rating on shares of Geron in a research report on Thursday, January 29th. Two research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, Geron presently has a consensus rating of “Hold” and an average price target of $2.17.

About Geron

Geron Corporation (NASDAQ: GERN) is a clinical-stage biotechnology company dedicated to developing and commercializing novel treatments that target telomerase, an enzyme critical to cancer cell immortality. The company’s research is focused on hematologic malignancies and solid tumors, with a pipeline designed to address diseases that have historically had limited therapeutic options.

The lead product candidate, imetelstat, is a first-in-class telomerase inhibitor currently in Phase II and Phase III clinical trials for myelofibrosis and myelodysplastic syndromes.